[HTML][HTML] Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee, JS Ahn… - Journal of Thoracic …, 2009 - Elsevier
Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
[HTML][HTML] Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee, JS Ahn, SW Kim… - Journal of Thoracic …, 2009 - jto.org
Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer A Multicenter Trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee… - JOURNAL OF …, 2009 - scholarworks.bwise.kr
Background: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
JE Uhm, BB Park, MJ Ahn, J Lee, JS Ahn… - Journal of Thoracic …, 2009 - europepmc.org
Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: A multicenter trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee… - Journal of Thoracic …, 2009 - snucm.elsevierpure.com
BACKGROUND: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer A Multicenter Trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee, JS Ahn… - JOURNAL OF …, 2009 - scholar.korea.ac.kr
Background: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
[PDF][PDF] Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer A Multicenter Trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee, JS Ahn, SW Kim… - 2009 - kumel.medlib.dsmc.or.kr
Background: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: A multicenter trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee, JS Ahn… - Journal of Thoracic …, 2009 - pure.korea.ac.kr
BACKGROUND: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: A multicenter trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee… - Journal of Thoracic …, 2009 - cuk.elsevierpure.com
BACKGROUND: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group
JE Uhm, BB Park, MJ Ahn, J Lee, JS Ahn, SW Kim… - 2009 - ir.ymlib.yonsei.ac.kr
BACKGROUND: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …